← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K992914 # EXCIMER LASER PHOTOTHERAPY SYSTEM, AL7000 (K992914) _Acculase, Inc. · GEX · Jan 27, 2000 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K992914 ## Device Facts - **Applicant:** Acculase, Inc. - **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md) - **Decision Date:** Jan 27, 2000 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use UVB phototherapy for Psoriasis ## Device Story The AL7000 is a compact, self-contained XeCl excimer laser system generating 308 nm ultraviolet light. The system comprises a keypad/display, fiberoptic delivery system, footswitch, and handpiece, all housed in a protective interlocked enclosure. Operated by clinicians in a medical setting, the device delivers targeted UV light to psoriatic lesions. The clinician uses the keypad to control the laser output, which is directed via the handpiece to the patient's skin. This localized phototherapy is intended to treat psoriasis symptoms. The device benefits patients by providing a controlled, targeted light source for dermatological therapy. ## Clinical Evidence Clinical evidence includes a dose-response study using a 308 nm excimer laser, which demonstrated the safety and effectiveness of the laser for the treatment of psoriasis. ## Technological Characteristics XeCl excimer laser; 308 nm wavelength; fiberoptic delivery system; keypad/display interface; protective interlocked housing; conforms to EN 60601 / IEC 601 series standards. ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Predicate Devices - HOUVA II, Phototherapy System ([K885026](/device/K885026.md)) - UviSol, Phototherapy System ([K934808](/device/K934808.md)) - CVX-300 Excimer Laser System ([P910001](/device/P910001.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ JAN 27 2000 : K 992914 ## 510(k) SUMMARY AccuLase, Inc. Excimer Laser Phototherapy System, AL7000 #### 1. GENERAL - . Submitter : AccuLase, Inc. 2431 Impala Drive Carlsbad, CA 92008 - Contact Person: Al Memmolo . - Dute Prepared: January 14, 1999 . #### 2. DEVICE NAME - . Classification nume: Ultraviolet lamp for dermatological disorders (ner 21 CFR 8878.4630) - Common or usual name: XeCl excimer laser . - . Trade or proprietary name: Excimer Laser Phototherapy System, AL7000 ### 3. PREDICATE DEVICES #### Ultraviolet Lamps - HOUVA II, Phototherapy System . National Biological Corporation 510(k) number: K885026 - UviSol, Phototherapy System . National Biological Corporation, 510(k) number K934808 #### Excimer Laser - CVX-300 Excimer Laser System . Spectranetics Corp. PMA number: P910001 {1}------------------------------------------------ #### 510 (k) Summary AL 7000 #### 4. DEVICE DESCRIPTION The Excimer Laser Phototherapy System, AL7000 is a complete self-contained compact laser light source, which utilizes a XeCl gas mixture to generate ultraviolet light at wavelength of 308 nm wavelength. The laser system consists of a keypad and display, a fiberoptic delivery system, a footswitch, and a handpiece. The laser is enclosed in a protective interlocked housing. #### 5. INTENDED USE UVB phototherapy for Psoriasis #### 6. SUBSTANTIAL EQUIVALENCE The intended use for the AccuLase Excimer Laser Phototherapy System, AL.7000 is identical to that of the predicate ultraviolet lamps. Both device types share the same methods and mechanisms of treatment. The Excimer Laser Phototherapy System is substantially equivalent to the technological characteristics of the predicate excimer laser device. Both devices share the same operating principles and produce un identical wavelength. #### 7. CI.INICAL PERFORMANCE DATA A dose response study using a 308 nm excimer laser showed the safety and effectiveness of the excimer laser for the treatment of Psoriasis. #### 8. PRODUCT PERFORMANCE TESTING Testing conducted on the Excimer Laser Phototherapy System, AL7000 includes conformance to all relevant International EN 60601 / IEC 601 series of standards and applicable laser standards. #### 9. CONCLUSIONS Based on the same intended use as ultraviolet lamps, the similar technological characteristics of the excimer lasers, and the clinical and performance data, AccuLase believes that the Excimer Laser Phototherapy System, AL7000 is substantially equivalent to the predicate devices. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or a stylized human figure. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JAN 27 2000 Mr. Al Memmolo Director, Quality Assurance and Regulatory Affairs AccuLase, Inc. 2431 Impala Drive Carlsbad, California 92008 Re: K992914 > Trade Name: Excimer Laser Phototherapy System, AL 7000 Regulatory Class: II Product Code: GEX Dated: November 24, 1999 Received: November 29, 1999 Dear Mr. Memmolo: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (OS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed {3}------------------------------------------------ Page 2 - Mr. Al Memmolo predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours poella James E. Dillard III Acting Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## AccuLase, Inc. ( a subsidiary of Laser Photonics, Inc.) # K992914 510(k) Number (if known): Device Name: Excimer Laser Phototherapy, AL 7000 Indications For Use: #### UVB Phototherapy for Psoriasis #### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) | | Concurrence of CDRH, Office of Device Evaluation (ODE) | |--|--------------------------------------------------------| |--|--------------------------------------------------------| | (Division Sign-Off) | | |-----------------------------------------|---------| | Division of General Restorative Devices | | | 510(k) Number | K992914 | | Prescription Use | X | OR | Over-The-Counter-Use | |----------------------|----------------------------------------------------|----|----------------------| | (Per 21 CFR 801.109) | | | | --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K992914](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K992914) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com